GIUSEPPE DI BELLA > INDICE DELLA DOCUMENTAZIONE > Area Pazienti - Documentazione

 
 
Area Pazienti - Documentazione
 
 
Epidermal growth factor receptor, C-kit, and Her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 World Health Organization in patients treated with octreotide and prednisone: an Eastern Cooperative Oncology Group study. (08/04/2011)
Dettaglio
Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction. (08/04/2011)
Dettaglio
VEGF secretion by neuroendocrine tumor cells is inhibited by octreotide and by inhibitors of the PI3K/AKT/mTOR pathway. (08/04/2011)
Dettaglio
Cancer: antitumor effects of octreotide LAR, a somatostatin analog. (08/04/2011)
Dettaglio
Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue (08/04/2011)
Dettaglio
Response of recurrent high-grade glioma to treatmentwith (90)Y-DOTATOC. (08/04/2011)
Dettaglio
Molecular imaging in thyroid cancer. (08/04/2011)
Dettaglio
Expression of somatostatin receptors in human melanomacell lines: effect of two different somatostatin analogues, octreotide andSOM230, on cell proliferation. (08/04/2011)
Dettaglio
Attenuation correction of somatostatin receptor SPECT by integrated low-dose CT: is there an impact on sensitivity? (08/04/2011)
Dettaglio
Management of coexisting thyrotropin/growth-hormone-secreting pituitary adenoma and papillary thyroid carcinoma: a therapeutic challenge (08/04/2011)
Dettaglio
Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. (08/04/2011)
Dettaglio
[A case of successful treatment using octreotide acetate for occlusive ileus in terminal stage cancer]. (08/04/2011)
Dettaglio
Octreotide LAR: safety and tolerability issues. (08/04/2011)
Dettaglio
Octreotide treatment of patients with hepatocellular carcinoma--a retrospective single centre controlled study. (08/04/2011)
Dettaglio
hSSTR2 expression and octreotide treatment reverses multidrug resistance of BxPC-3 human pancreatic cancer cells. (08/04/2011)
Dettaglio
 
 
 
Scorri con le frecce per visualizzare le pagine della ricerca 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 |
 
 

Stampa